Abstract
Myristoyl-CoA:Protein N-myristoyltranferase (NMT) is a cytosolic monomeric enzyme which catalyses the transfer of a rare fatty acid , myristate from myristoyl-CoA to the N-terminal glycine residue of a variety of eukaryotic and viral proteins. N-myristoyltransferase is a novel target for Anticancer, Antiviral and antifungal agents. Recent Nmyristoyltransferase inhibitors like benzofurans and benzothiazole derivatives show in vivo antifungal activity and are promising selective fungal N-myristoyltransferase inhibitors.
Keywords: N-myristoyltransferase, myristoylation, benzofurans, benzothiazoles, antifungal, Candida albicans, anticancer, antiviral
Mini-Reviews in Medicinal Chemistry
Title: N-Myristoyltransferase: A Novel Target
Volume: 8 Issue: 2
Author(s): M. P. Toraskar, K. K. Prasad and V. J. Kadam
Affiliation:
Keywords: N-myristoyltransferase, myristoylation, benzofurans, benzothiazoles, antifungal, Candida albicans, anticancer, antiviral
Abstract: Myristoyl-CoA:Protein N-myristoyltranferase (NMT) is a cytosolic monomeric enzyme which catalyses the transfer of a rare fatty acid , myristate from myristoyl-CoA to the N-terminal glycine residue of a variety of eukaryotic and viral proteins. N-myristoyltransferase is a novel target for Anticancer, Antiviral and antifungal agents. Recent Nmyristoyltransferase inhibitors like benzofurans and benzothiazole derivatives show in vivo antifungal activity and are promising selective fungal N-myristoyltransferase inhibitors.
Export Options
About this article
Cite this article as:
Toraskar P. M., Prasad K. K. and Kadam J. V., N-Myristoyltransferase: A Novel Target, Mini-Reviews in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/138955708783498159
DOI https://dx.doi.org/10.2174/138955708783498159 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Look for Changes in 2016
Current Molecular Medicine Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Current Pharmaceutical Design The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers
Current Medicinal Chemistry - Anti-Cancer Agents Is it Possible to Reduce the Incident of Colorectal Cancer by Modifying Diet and Lifestyle?
Current Cancer Therapy Reviews <sup>90</sup>Y-DOTA-Nimotuzumab: Synthesis of a Promising β− Radiopharmaceutical
Current Radiopharmaceuticals Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology MRI of Focal Liver Lesions
Current Medical Imaging Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Editorial (Hot Topic: Cross-Talking Metabolism and Epigenetics in Anti-Cancer Drug Design)
Current Pharmaceutical Design Resistance to Peloruside A and Laulimalide: Functional Significance of Acquired βI-tubulin Mutations at Sites Important for Drug-Tubulin Binding
Current Cancer Drug Targets ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals